Study of REGN5678 plus cemiplimab for advanced prostate cancer
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This trial tests a combination of two drugs (REGN5678 and cemiplimab) for men with metastatic castration-resistant prostate cancer that has progressed after at least two prior treatments. The goal is to see if this new combination can help shrink the cancer or slow its growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be a man 18 years or older with prostate cancer that has spread and is no longer responding to hormone therapy.
- Your cancer must have gotten worse after at least two previous treatments, including one type of newer hormone therapy.
- You must have had your testicles removed or be on hormone-blocking medication to keep testosterone levels very low.
- You must be well enough to be up and about (ECOG score 0 or 1).
- Your blood counts, kidney, and liver function must be within certain limits.
- You cannot have serious heart problems, active infections, or a condition that weakens your immune system.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study combines two treatments: pembrolizumab, which helps your immune system fight cancer, and a targeted radioactive medicine (177Lu-PSMA-617) that seeks out and damages prostate cancer cells. It may help men whose prostate cancer has spread despite initial hormone therapy.
This early-phase trial tests pembrolizumab (an immune therapy) plus an androgen-receptor–blocking prostate cancer drug, and possibly a targeted radiation treatment. It’s for men with prostate cancer that has spread and keeps worsening despite standard hormone therapy, aiming to shrink tumors and improve control of the disease.
This early trial tests whether REGN5678 (nezastomig) is safe and how well it works, either by itself or with an immunotherapy drug (cemiplimab). It targets adults with metastatic castration-resistant prostate cancer and certain metastatic kidney cancers that have already been treated.
This trial tests new experimental drugs (REGN15505 and REGN4336) designed to target and attack cancer cells in advanced prostate cancer or kidney cancer. These drugs work by boosting your immune system to recognize and destroy cancer, and may be combined with other approved immunotherapy drugs.
This early-phase study tests whether REGN4336 is safe and how well it works, by itself or with REGN5678, in adults with advanced prostate cancer. It may help people whose cancer has continued to worsen despite standard prostate cancer medicines.
This study tests two new drugs, regn21353 and nezastomig, alone or together, in men with advanced prostate cancer that has stopped responding to hormone therapy. The goal is to see if these drugs can help slow the cancer's growth.
Hear when a new Prostate cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.